IP40 Stock Chart & Stats
€1.48
€0.00(0.00%)
At close: 4:00 PM EDT
€1.48
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.21 - €13.20
Previous CloseN/A
Volume0.00
Average Volume (3M)111.00
Market Cap
€5.61M
Enterprise Value€8.16
Total Cash (Recent Filing)€6.44M
Total Debt (Recent Filing)€1.66M
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding4,498,772
10 Day Avg. Volume21
30 Day Avg. Volume111
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsGross margins near 90% indicate favorable product economics and leave substantial revenue available to cover operating costs, fund research, and support commercialization. If maintained, this margin profile can provide meaningful operating leverage as sales scale, even though the company is not yet profitable.
Moderate LeverageModerate leverage and positive equity provide some balance-sheet support while InnoCan works toward profitability. This gives the company more financial flexibility than a highly indebted business, although that cushion could weaken if losses and cash consumption continue.
Narrowing LossesThe substantial reduction in losses compared with earlier years suggests progress toward improving operating economics and eventual profitability. Continued loss reduction would strengthen internal funding capacity and reduce dependence on external capital as the pharmaceutical and product businesses develop.
Bears Say
Revenue ContractionRecent revenue softness indicates that product demand or commercial execution is not currently expanding consistently. Persistent contraction would limit the company’s ability to absorb fixed costs, invest in its pipeline, and convert strong gross margins into sustainable operating profits.
Persistent UnprofitabilityOngoing net and operating losses show that strong gross margins have not yet translated into a viable earnings model. Continued unprofitability can constrain reinvestment, increase reliance on financing, and delay the point at which the business can fund growth from internally generated earnings.
Cash Burn And Rising LeverageNegative operating and free cash flow means the company is currently consuming cash rather than funding operations internally. If the burn persists, rising leverage may become a more important constraint, increasing potential funding needs and reducing flexibility to advance development programs.
InnoCan Pharma News
IP40 FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was €1.21 and its highest was €13.20 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is €5.61M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Dec 02, 2026 which is in 78 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on Aug 31, 2026. The company reported -€0.006 earnings per share for the quarter.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -€0.006 in its last earnings report. Following the earnings report the stock price went up 5.396%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in DE:IP40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.